Related Experiment Video
Updated: Jun 14, 2025
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Autofluorescent Cancer Stem Cells: Potential Biomarker to Predict Recurrence in Resected Colorectal Tumors
Sonia Alcala1,2, Gonzalo Serralta San Martin3,4, Marta Muñoz-Fernández de Legaria5
1Department of Biochemistry, School of Medicine, Autónoma University of Madrid and Department of Cancer, Instituto de Investigaciones Biomédicas (IIBm) Sols-Morreale (CSIC-UAM), Madrid, Spain.
High autofluorescence cancer stem cells (AF CSCs) in colorectal cancer indicate a higher risk of relapse, especially when lymph node metastases are present. This finding suggests AF CSCs can serve as a prognostic biomarker for patient management.
Area of Science:
- Oncology
- Cancer Biology
- Biomarker Discovery
Background:
- Colorectal cancer (CRC) exhibits intratumoral heterogeneity and distant metastases driven by cancer stem cells (CSCs).
- Autofluorescence (AF) has been identified as a method for detecting CSCs.
- The prognostic value of AF CSCs in CRC relapse has not been previously investigated.
Purpose of the Study:
- To evaluate the prognostic potential of AF CSCs as a biomarker for CRC relapse.
- To correlate AF CSC levels with histological and clinical outcomes in CRC patients.
Main Methods:
- Seventy-five resected CRC tumors were analyzed using flow cytometry to quantify AF CSCs.
- AF was categorized as high (H-AF) or low.
- Results were correlated with histological features (differentiation grade, lymph node (LN) metastasis, invasion) and clinical data (relapse time, survival).
Main Results:
- 25.3% of patients experienced relapse; 13 had positive LNs, 6 had H-AF.
- Patients with H-AF CSCs showed a 1.5-fold increased risk of relapse.
- H-AF CSCs combined with LN metastases significantly elevated relapse risk (HR 7.92, P < 0.004).
Conclusions:
- AF is a feasible and accurate marker for identifying CSCs in resected CRC.
- H-AF CSCs are strongly associated with increased relapse risk, particularly in patients with positive LNs.
- H-AF CSCs may identify patients who could benefit from adjuvant chemotherapy and intensive surveillance for CRC recurrence.
